|
A classification system for urothelial carcinoma (UC) defined by genomic drivers and the tumor microenvironment (TME) is predictive of immunotherapy response. |
|
|
|
Patents, Royalties, Other Intellectual Property - BostonGene (Inst) |
|
|
|
Patents, Royalties, Other Intellectual Property - BostonGene (Inst) |
|
|
|
Stock and Other Ownership Interests - Aptinyx; Moderna Therapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - BostonGene |
Patents, Royalties, Other Intellectual Property - I am authors in six patents owned by BostonGene; I am authors in six patents owned by BostonGene |
Travel, Accommodations, Expenses - BostonGene |